Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Calls for Ongoing Nitrosamine Risk Controls after Self-Inspections
July 24, 2025
- 223 Health Damages Reported for Breyanzi in Japan: October-March
July 24, 2025
- MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End
July 24, 2025
- New MHLW Drug Review Chief Aims to Dispel “Barrier” Perception, Pledges Active Engagement with Industry
July 23, 2025
- Healthcare Stakeholders Weigh Fallout after Ruling Bloc’s Election Setback
July 23, 2025
- Astellas Employee Won’t Appeal China Espionage Sentence
July 22, 2025
- Japan’s Ruling Bloc Routed in Upper House Poll; Takemi to Retire, Furukawa, Kamayachi, and Honda Secure Seats
July 22, 2025
- Japan Panel to Review MSD’s 21-Valent Pneumococcal Shot, Silgard 9 for Male Use and More Label Expansions
July 18, 2025
- Japan Approves Reimbursement for CureApp’s Alcohol Reduction Digital Therapeutic
July 17, 2025
- Japan Begins FY2026 CEA Reform Talks, Re-Designation after Market Expansion Up for Debate
July 17, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Japan’s Major Parties Outline Various Drug Policy Visions Ahead of Upper House Poll
July 14, 2025
- Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
July 11, 2025
- Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
July 11, 2025
- 16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
July 10, 2025
- Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
- Janssen’s Balversa Gets Green Light for NHI Listing
July 10, 2025
- Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
- Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…